Trial site
Rio de Janeiro
Rio de Janeiro, 20231-050, BrazilNot linked to an institution yet
- 9running trials
- 4closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 11 trial
- Phase 21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting7 trials
- Completed4 trials
- Recruiting2 trials
- Lead sponsor
- GlaxoSmithKline8 trials
- ViiV Healthcare4 trials
- Tesaro, Inc.1 trial
Running trials
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916· Phase 3· ViiV Healthcare· Source
Contact: Beatriz Gilda Grinsztejn (principal investigator)
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898· Phase 3· GlaxoSmithKline· Source
Contact: Tatiane Montella (principal investigator)
Active, not recruiting
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
NCT06134362· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
NCT04655976· Phase 2/3· GlaxoSmithKline· Source
Active, not recruiting
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· Phase 1· Tesaro, Inc.· Source
Active, not recruiting
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503· Phase 3· ViiV Healthcare· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error